I don't know what's ORR will be in ph2b, mainly because the uncertainty from replicating small trial result in larger trials. All I was pointing out was ph2b isn't for all GPNMA positive population, it is for GPNMB positive sub population only. Any number anyone comes up with is either from really small sample (20%) or a sample isn't from the same population (10%). I am more interested in PFS than ORR from ph2b.
Market Data 
Markets 
AI
